Allergic asthma: What have we learned from the mouse model?

Allergology International

Volumn 54, Issue 2, 2005, Pages 263-271

  Takeda, Katsuyuki ^a   Dakhama, Azzeddine ^a   Gelfand, Erwin W ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Allergy; Asthma; Interleukin 13; Mast cell; Mouse; T lymphocyte

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CORTICOSTEROID; CYTOKINE; HISTAMINE; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 13; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ALLERGIC ASTHMA; BRONCHUS HYPERREACTIVITY; CORTICOSTEROID THERAPY; DISEASE MODEL; DRUG EFFICACY; EFFECTOR CELL; HUMAN; INFLAMMATORY CELL; LUNG FUNCTION; MAST CELL; MEDIATOR RELEASE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RESPIRATORY TRACT INFLAMMATION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 21144455347     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.2332/allergolint.54.263     Document Type: Review

References (75)

1. Larsen GL, White CW, Takeda K et al. Mice that overexpress Cu / Zn superoxide dismutase are resistant to allergen-induced changes in airway control. Am. J. Physiol. Lung Cell Mol. Physiol. 2000;279:L350-359.
2. Kanehiro A, Ikemura T, Makela MJ et al. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am. J. Respir. Crit. Care Med. 2001; 163:173-184.
3. Hamelmann E, Oshiba A, Loader J et al. Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am. J. Respir. Crit. Care Med. 1997;155:819-825.
4. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
5. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes : role of age at onset and eosinophilic inflammation. J. Allergy Clin. Immunol. 2004;113:101-108.
6. Milgrom H, Fick RB Jr, Su JQ et al. Treatment of allergic asthma with monoclonal anti-ige antibody. Rhumab-E25 Study Group. N. Engl. J. Med. 1999;341:1966-1973.
7. Kallos P, Kallos L. Experimental asthma in guinea pigs revisited. Intl. Arch. Allergy Appl. Immunol. 1984;73:77-85.
8. Vargaftig BB. Modifications of experimental bronchopulmonary hyperresponsiveness. Am. J. Respir. Crit. Care Med. 1997;56:897-102.
9. Lahn M, Kanehiro A, Takeda K et al. Negative regulation of airway responsiveness that is dependent on gammadelta T cells and independent of alphabeta T cells. Nature Med. 1999;6:1150-1156.
10. Haczku A, Takeda K, Hamelmann E et al. CD23 deficient mice develop allergic airway hyperresponsiveness following sensitization with ovalbumin. Am. J. Respir. Crit. Care Med. 1997;56:1945-1955.
11. Irvin CG, Bates JH. Measuring the lung function in the mouse : the challenge of size. Respir. Res. 2003;4:4-12.
12. Takeda K, Hamelmann E, Joetham A et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J. Exp. Med. 1997;186:449-454.
13. Hamelmann E, Takeda K, Schwarze J, Vella AT, Irvin CG, Gelfand EW. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am. J. Respir. Cell Mol. Biol. 1999;21:480-489.
14. Tomkinson A, Duez C, Lahn M, Gelfand EW. Adoptive transfer of T cells induces airway hyperresponsiveness independently of airway eosinophilia but in a signal transducer and activator of transcription 6-dependent manner. J. Allergy Clin. Immunol. 2002;109:810-816.
15. Tomkinson A, Kanehiro A, Rabinovitch N, Joetham A, Cieslewicz G, Gelfand EW. The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5. Am. J. Respir. Crit. Care Med. 1999;160:1283-1291.
16. Hamelmann E, Takeda K, Haczku A et al. Interleukin (IL)-5 but not immunoglobulin E reconstitutes airway inflammation and airway hyperresponsiveness in IL-4-deficient mice. Am. J. Respir. Cell Mol. Biol. 2000;23:327-334.
17. Taube C, Duez C, Cui ZH et al. The role of IL-13 in established allergic airway disease. J. Immunol. 2002;169: 6482-6489.
18. Kobayashi T, Iijima K, Kita H. Marked airway eosinophilia prevents development of airway hyperresponsiveness during an allergic response in IL-5 transgenic mice. J. Immunol. 2003;170:5756-5763.
19. Cui ZH, Joetham A, Aydintug MK, Hahn YS, Born WK, Gelfand EW. Reversal of allergic airway hyperreactivity after long-term allergen challenge depends on gammadelta T cells. Am. J. Respir. Crit. Care Med. 2003;168: 1324-1332.
20. Hamelmann E, Tadeda K, Oshiba A, Gelfand EW. Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness-A murine model. Allergy 1999;54:297-305.
21. Larsen GL, Renz H, Loader JE, Bradley KL, Gelfand EW. Airway response to electrical field stimulation in sensitized inbred mice. Passive transfer of increased responsiveness with peribronchial lymph nodes. J Clin. Invest. 1992;89:747-752.
22. Oshiba A, Hamelmann E, Takeda K et al. Passive transfer of immediate hypersensitivity and airway hyperresponsiveness by allergen-specific immunoglobulin (Ig) E and IgG1 in mice. J. Clin. Invest. 1996;97:1398-1408.
23. Wills-Karp M, Luyimbazi J, Xu X et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282: 2258-2261.
24. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol. Rev. 1997;77:1033-1038.
25. Takeda K, Hamelmann E, Joetham A et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J. Exp. Med. 1997;186:449-454.
26. Cony DB, Kheradmand F. Biology and therapeutic potential of the interleukin-4/interleukin-13 signaling pathway in asthma. Am. J. Respir. Med. 2002;1:185-193.
27. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. 1993;12:2663-2670.
28. Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J. Exp. Med. 1995;181: 1373-1380.
29. Taube C, Wei X, Swasey CH et al. Mast cells, Fcepsilon RI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant. J. Immunol. 2004;172:6398-6406.
30. Naclerio R. Clinical manifestations of the release of histamine and other inflammatory mediators. J. Allergy Clin. Immunol. 1999;103:382-385.
31. Novak I, Falus A. Molecular biology and role of histamine in physiological and pathological reactions: a review. Acta Biol. Hung. 1997;48:385-394.
32. Warner JO, ETAC Study Group. Early Treatment of the Atopic Child. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months treatment and 18 months' posttreatment follow-up. J. Allergy Clin. Immunol. 2001;108:929-937.
33. Gelfand EW, Cui ZH, Takeda K, Kanehiro A, Joetham A. Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J. Allergy Clin. Immunol. 2002;110:85-95.
34. Bryce PJ, Geha R, Oettgen HC. Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. J. Allergy Clin. Immunol. 2003;112: 149-158.
35. Chain BM. Current issues in antigen presentation-focus on the dendritic cell. Immunol. Lett. 2003;89:237-241.
36. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nature Immunol. 2001;2: 725-731.
37. Chambers SJ, Bertelli E, Winterbone MS, Regoli M, Man AL, Nicoletti C. Adoptive transfer of dendritic cells from allergic mice induces specific immunoglobulin E antibody in naive recipients in absence of antigen challenge without altering the T helper 1/T helper 2 balance. Immunology 2004;112:72-79.
38. Caron G, Delneste Y, Roelandts E et al. Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J. Immunol. 2001;166: 6000-6006.
39. Miki I, Kusano A, Ohta S et al. Histamine enhanced the TNF-alpha-induced expression of E-selectin and ICAM-1 on vascular endothelial cells. Cell Immunol. 1996;171: 285-288.
40. Paolieri F, Battifora M, Riccio AM et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression in human continuous cell lines. Ann. Allergy Asthma Immunol. 1998;81:601-607.
41. Fukuishi N, Matsuhisa M, Shimono T et al. Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils. Jpn. J. Pharmacol. 2002;88:463-466.
42. Bachert C. The role of histamine in allergic disease: reappraisal of its inflammatory potential. Allergy 2002;57: 287-296.
43. Jeannin P, Delneste Y, Gosset P et al. Histamin induces interlukin-8 secretion by endothelial cells. Blood 1994;84: 2229-2233.
44. Delneste Y, Lassalle P, Jeannin P, Joseph M, Tonnel AB, Gosset P. Histamine induces IL-6 production by human endothelial cells. Clin. Exp. Immunol. 1994;98:344-349.
45. Vannier E, Dinarello CA. Histamine enhances interleukin (IL)-1-induced IL-1 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells: comparison with IL-1 receptor antagonist. J. Clin. Invest. 1993;92:281-287.
46. Mor S, Nagler A, Barak V, Handzel ZT, Geller-Gernstein C, Fabian I. Histamine enhances granulocyte-macrophage colony-stimulating factor and interleukin-6 production by human peripheral blood mononuclear cells. J. Leukoc. Biol. 1995;58:445-450.
47. Kohka H, Nishibori M, Iwagaki H et al. Histamine is a potent inducer of IL-18 and IFN- in human peripheral blood mononuclear cells. J. Immunol. 2000;164:6640-6646.
48. Triggiani M, Gentile M, Seconde A et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J. Immunol. 2001;166:4083-4091.
49. Elenkov U, Webster E, Papanicolaou DA et al. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J. Immunol. 1998;161:2586-2593.
50. Triggiani M, Gentile M, Secondo A et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J. Immunol. 2001;166:4083-4091.
51. Elenkov U, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J. Immunol. 1998;161:2586-2593.
52. Simons REF, Simons KJ. Antihistamines. In: Middleton F Jr, Reed CE, Ellis EF (eds). Allergy: principles and practice. 4th edn. St. Louis: Mosby Year Book, 1993;856-878.
53. Lichtenstein LM, Henney CS. Adenylate cyclase-linked hormone receptors : an important mechanism for the immunoregulation of leukocytes. Prog. Immunol. 1976;2:73-83.
54. Busse WW, Coffman RL, Gelfand EW, Kay AB, Rosenwasser LJ. Mechanisms of persistent airway inflammation in asthma: a role for T cells and T-cell products. Am. J. Respir. Crit. Care Med. 1995;152:388-393.
55. Cohn L, Tepper JS, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J. Immunol. 1998;161:3813-3816.
56. Gavett SH, Chen X, Finkelman F, Wills-Karp M. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am. J. Respir. Cell Mol. Biol. 1994;10:587-593.
57. Grunig G, Warnock M, Wakil AE et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-2263.
58. McKenzie GJ, Emson CL, Bell SE et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998; 9:423-432.
59. Olivenstein R, Renzi PM, Yang JP et al. Depletion of OX-8 lymphocytes from the blood and airways using monoclonal antibodies enhances the late airway response in rats. J. Clin. Invest. 1993;92:1477-1482.
60. Huang TJ, MacAry PA, Kemeny DM, Chung KF. Effect of CD8+ T-cell depletion on bronchial hyper-responsiveness and inflammation in sensitized and allergen-exposed Brown-Norway rats. Immunology 1999;96:416-423.
61. Szuki M, Taha R, Ihaku D, Hamid Q, Martin JG. CD8+ T cells modulate late allergic airway responses in Brown-Norway rats. J. Immunol. 1999;163:5574-5581.
62. Miyata S, Matsuyama T, Kodama T et al. STAT 6 deficiency in a mouse model of allergen-induced airways inflammation abolishes eosinophilia but induces infiltration of CD8+ T cells. Clin. Exp. Allergy 1999;29:114-123.
63. Gonzalez MC, Diaz P, Galleguillos FR, Ancic P, Cromwell O, Kay AB. Allergen-induced recruitment of bronchoalveolar helper (OKT4) and suppressor (OKT8) T-cells in asthma: relative increases in OKT8 cells in single early responders compared with those in late-phase responders. Am. Rev. Respir. Dis. 1987;136:600-604.
64. Hamelmann E, Oshiba A, Paluh J et al. Requirement for CD8+ T cells in the development of airway hyperresponsiveness in a murine model of airway sensitization. J Exp. Med. 1996;183:1719-1729.
65. Erard F, Wild MT, Garcia-Sanz JA, Le Gros G. CD8+ lymphocytes can develop into non-cytolytic CD8-CD4- cells which produce IL-4, IL-5, IL-10, and help B cells. Science 1993;260:1802-1805.
66. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995;2:271-279.
67. Cerwenka A, Carter LL, Reome JB, Swain SL, Dutton RW. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines. J. Immunol. 1998;161: 97-105.
68. O' Sullivan S, Cormican L, Faul JL et al. Activated, cytotoxic CD8+ T lymphocytes contribute to the pathology of asthma death. Am. J. Respir. Crit. Care Med. 2001;164: 560-564.
69. Cho SH, Stanciu LA, Begishivili T, Bates PJ, Holgate ST, Johnston SL. Peripheral blood CD4+ and CD8+ T cell type 1 and type 2 cytokine production in atopic and normal subjects. Clin. Exp. Allergy 2002;32:427-433.
70. Miyahara N, Takeda K, Kodama T et al. Contribution of antigen-primed CD8+ T cells to the development of airway-hyperresponsiveness and inflammation is associated with IL-13. J. Immunol. 2004;172:2549-2558.
71. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401: 708-712.
72. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001;291:2413-2417.
73. Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8+ T cells. J. Exp. Med. 2001;194:953-966.
74. Miyahara N, Swanson BJ, Takeda K et al. Effector CD8 (+) T cells mediate inflammation and airway hyperresponsiveness. Nature Med. 2004;10:865-869.
75. Ott VL, Gambier JC, Kappler J, Marrack P, Swanson BJ. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nature Immunol. 2003;4:974-981.